PT - JOURNAL ARTICLE AU - Vargas, Leonardo AU - Valdivieso, Nicolás AU - Tempio, Fabián AU - Simon, Valeska AU - Sauma, Daniela AU - Valenzuela, Lucía AU - Beltrán, Caroll AU - Castillo-Delgado, Loriana AU - Contreras-Benavides, Ximena AU - Acevedo, Mónica L. AU - Valiente-Echeverría, Fernando AU - Soto-Rifo, Ricardo AU - Gonzalez, Rafael I. AU - Lopez, Mercedes AU - Osorio, Fabiola AU - Bono, María Rosa TI - Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 S antibodies AID - 10.1101/2022.01.14.22269289 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.14.22269289 4099 - http://medrxiv.org/content/early/2022/01/23/2022.01.14.22269289.short 4100 - http://medrxiv.org/content/early/2022/01/23/2022.01.14.22269289.full AB - Background Chile was severely affected by COVID19 outbreaks but was also one of the first countries to start a nationwide program to vaccinate against the disease. Furthermore, Chile became one of the fastest countries to inoculate a high percentage of the target population and implemented homologous and heterologous booster schemes in late 2021 to prevent potential immunological waning. The aim of this study is to compare the immunogenicity and time course of the humoral response elicited by the CoronaVac vaccine in combination with homologous versus heterologous boosters.Methods and Findings We compared the immunogenicity of two doses of CoronaVac and BNT162b2 vaccines and studied the effect of different booster regimes in the Chilean population. Our results demonstrate that a two-dose vaccination scheme with CoronaVac induces lower levels of anti-SARS-CoV-2 S antibodies than BNT162b2 in a broad age range. Furthermore, antibody production declines with time in individuals vaccinated with CoronaVac and less noticeably, with BNT162b2. Remarkably, analysis of booster schemes revealed that individuals vaccinated with two doses of CoronaVac generate immunological memory against the SARS-CoV-2 ancestral strain, which can be re-activated with homologous or heterologous (BNT162b2 and ChAdOx1) boosters. Nevertheless, the magnitude of the antibody response with the heterologous booster regime was considerably higher and persistent (over 100 days) than the responses induced by the homologous scheme.Conclusions Two doses of CoronaVac induces antibody titers against the SARS-CoV-2 ancestral strain which are lower in magnitude than those induced by the BNT162b2 vaccine. However, the response induced by CoronaVac can be greatly potentiated with a heterologous booster scheme with BNT162b2 or ChAdOx1 vaccines. Furthermore, the heterologous booster regimes induce a durable antibody response which does not show signs of decay 3 months after the booster dose.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the COVID-19 research program of the National Agency for Research and Development (ANID), grant No 0752 (MRB, FO, ML). MRB and DS are supported by ANID/BASAL/FB210008, and FONDECYT grants No 1191438 (MRB) and 1180385 (DS). FO is supported by an International Research Scholar grant from HHMI (HHMI#55008744), a FONDECYT grant No. 1200793, and ECOS-CONICYT grant (ECOS180052). CB is supported by a FONDECYT grant No 1181699. RSR is supported by a FONDECYT grant No 1190156. FVE is supported by a FONDECYT grant No 1211547. RG is supported by FONDECYT grants No 11180557 and CEDENNA AFB180001. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Hospital Clinico Universidad de Chile approved the study on health worker personnel (Protocol ID Number 1151/20 and Protocol ID Number 074-2020). Facultad de Ciencias, Universidad de Chile (Protocol ID 2123-FCS-UCH and consent approval).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.